clinical trial · NCT07136012
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
Cardiovascular DiseaseOlpasiranPlacebo
brief summary
The primary objective is to evaluate the effect of olpasiran, compared to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants at risk for a first major cardiovascular event with elevated lipoprotein(a) (Lp\[a\]).
started
Aug 22, 2025
primary completion
Oct 20, 2031
completion
Oct 20, 2031
last updated
Jun 18, 2026
official title
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol